Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prediction and Prediction Error in Autism: A Meta-Analysis of Functional Magnetic Resonance Imaging Results.

Biological psychiatry global open science·2026
Same author

Predictors of unacceptable pain and the impact of sociodemographic factors and comorbidities-results from a large, nationwide cohort of early rheumatoid arthritis.

Annals of the rheumatic diseases·2026
Same author

Evaluating the ability of a thermal biology-informed reproduction number to explain patterns of West Nile incidence in Europe.

One health (Amsterdam, Netherlands)·2026
Same author

Corticostriatal connectivity in monozygotic twin pairs discordant for obsessive-compulsive disorder.

Brain : a journal of neurology·2026
Same author

Pain perception is not modulated by the rubber hand illusion in healthy participants: Insights from a systematic literature review and meta-analysis.

Neuroscience and biobehavioral reviews·2026
Same author

Towards a tool to discriminate between pain mechanistic descriptors: expert ranking of clinical features and allocation of weights using a forced choice paradigm.

Pain·2026

Related Experiment Video

Updated: May 21, 2026

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers
08:33

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

Published on: January 5, 2024

Cerebral Pain Processing Following TNFα Inhibitor Treatment in Rheumatoid Arthritis: A Randomized Double-Blind

Julie Klinke1, Peter Fransson1, Karin B Jensen1

  • 1Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

ACR Open Rheumatology
|May 20, 2026
PubMed
Summary

Tumor necrosis factor α (TNFα) blockade with adalimumab (ADA) did not alter brain pain processing in rheumatoid arthritis (RA) patients. Cerebral pain processing changes did not predict treatment response in this study.

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

Related Experiment Videos

Last Updated: May 21, 2026

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers
08:33

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

Published on: January 5, 2024

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

Area of Science:

  • Neuroscience
  • Immunology
  • Rheumatology

Background:

  • Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting joints and potentially causing central pain sensitization.
  • Tumor necrosis factor α (TNFα) inhibitors, like adalimumab (ADA), are effective in managing RA symptoms by blocking pro-inflammatory cytokines.
  • Understanding the central effects of TNFα blockade on pain processing in RA is crucial for optimizing treatment strategies.

Purpose of the Study:

  • To investigate the impact of adalimumab (ADA) treatment on brain pain processing in patients with rheumatoid arthritis (RA).
  • To identify potential pretreatment markers within cerebral pain pathways that predict treatment response to ADA in RA patients.

Main Methods:

  • A randomized, placebo-controlled trial involving 25 RA patients treated with ADA or placebo for four weeks.
  • Functional magnetic resonance imaging (fMRI) was used to assess brain activity during pain stimulation before and after treatment.
  • Pain sensitivity was evaluated using calibrated pressure-pain stimuli on inflamed and control joints.

Main Results:

  • Adalimumab (ADA) treatment led to significant improvements in subjective, clinician-rated, and objective measures of RA, unlike placebo.
  • While both groups showed brain activation in pain-relevant regions, no significant changes in cerebral activation were observed post-treatment in either group.
  • Baseline brain activation patterns did not correlate with changes in systemic inflammation (erythrocyte sedimentation rate) or clinical outcomes like pain and fatigue.
  • Exploratory analysis revealed correlations between baseline activation clusters and changes in swollen joint count in the ADA group.

Conclusions:

  • The study found no association between TNFα inhibitor treatment (adalimumab) and alterations in cerebral pain processing in RA patients.
  • These findings suggest that adalimumab may not exert a significant central effect on pain processing pathways in the context of rheumatoid arthritis.
  • Further research is needed to fully elucidate the central mechanisms underlying pain in RA and the impact of biologic therapies.